相关实验视频
Updated: Jun 14, 2025

08:48
Author Spotlight: Decoding Mitochondrial Aging
Published on: June 30, 2023
3.7K
药物向缓解阿尔茨海默病中的线粒体功能障碍:最近的进展和治疗影响
Md Ataur Rahman1,2,3, M D Hasanur Rahman1, Hyewhon Rhim4,5
1Department of Pathology, College of Korean Medicine, Kyung Hee University, Hoegidong Dongdaemungu, Seoul, 02447, South Korea.
Current neuropharmacology
|September 5, 2024
概括
阿尔茨海默病涉及线粒体功能障碍,影响能量,导致氧化应激. 本综述探讨了治疗策略,以纠正这些线粒体缺陷的潜在的新阿尔茨海默氏症治疗.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响认知,特别是在老年人中.
- 线粒体功能障碍越来越被认为是AD病变的关键因素,尽管其精确的机制仍在调查中.
- 损坏的线粒体生物能学,电子运输链缺陷和氧化应激是AD相关的线粒体妥协的标志.
研究的目的:
- 审查阿尔茨海默病中线粒体功能障碍背后的分子机制.
- 讨论当前和潜在的治疗方法,针对AD中的线粒体缺陷.
- 突出基于纠正线粒体功能障碍的新药开发潜力.
主要方法:
- 关于阿尔茨海默病和线粒体功能研究的文献综述.
- 分析涉及线粒体功能障碍的分子途径 (例如,DNA突变,氧化应激,神经炎症).
- 检查临床前和临床试验数据,以治疗针对AD的线粒体功能障碍.
主要成果:
- 阿尔茨海默氏症中的线粒体功能障碍与生物能学受损,电子运输链问题以及反应性氧物种 (ROS) 生产增加有关.
- 衰老加剧了线粒体衰退,导致氧化应激和AD中的神经炎症.
- 遗传因素 (核和线粒体DNA突变) 可以在早期AD阶段启动线粒体功能障碍.
结论:
- 纠正线粒体功能障碍为阿尔茨海默病提供了一个有希望的治疗途径.
- 对分子机制和药物开发的进一步研究对于有效的AD干预至关重要.
- 准线粒体健康可能会提供新的策略来对抗AD中与年龄相关的神经退行.
更多相关视频
相关概念视频
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
Electron Transport Chain: Complex I and II
12.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.3K
Mitochondria
11.5K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
11.5K
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K

